Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone
, considering 24-hour variation.
(Approved in 2000) [Fellman RL, Sullivan EK, Ratliff M, et al].
There are no human eye data for unoprostone
isopropyl (Rescula), a synthetic docosanoid.
is already available as Rescula (Sucampo Pharmaceuticals) in the United States, Japan and several South American countries.
isopropyl may have a local effect on BK (Big Potassium) channels in the eye.
2,4,6) Mechanism Drug Class Preparations of Action Reduction Adrenergic Brimonidine of Aqueous agonists Apraclonidine Inflow [beta]-blockers Non-selective Timolol Levobunolol Carteolol Selective [beta]-blockers Betaxolol Carbonic Systemic anhydrase Acetazolamide inhibitors Methazolamide Dichlorphenamide Topical Dorzolamide Brinzolamide Increase Cholinergics Pilocarpine in Aqueous Increase Carbachol Outflow trabecular outflow Prostaglandins Latanoprost (xalatan) and other lipid Travoprost (travatan) receptor agonists Increase Bimatoprost (lumigan) uveoscleral Unoprostone
outflow Table 2: The Demographic Data of the Patients of POAG Selected for the Study Bimatoprost Timolol Maleate No.
M2 PHARMA-March 9, 2015-Sucampo to return all licenses for intraocular pressure compound Unoprostone
Isopropyl to R-Tech Ueno
NASDAQ: SCMP) today announced that the Japan Science and Technology Agency (JST) has adopted unoprostone
isopropyl ophthalmic solution .
isopropyl, which is a member of its family of prostones and a synthetic docosanoid, may have a local effect on BK channels in the eye.
TOKYO -- R-Tech Ueno (JASDAQ:4573) is pleased to announce that the unoprostone
(development code: UF-021) ophthalmic solution currently in development as a treatment of retinitis pigmentosa(Note 1) (product name: Ocuseva(TM)) has been adopted in the Adaptable and Seamless Technology Transfer Program through Target-Driven R&D (A-STEP) public recruitment as "Full-scale R&D Stage - Practical Application Type (Contract Development)(Note 2")by the Japan Science and Technology Agency (JST) and that we have concluded an agreement on new technology contract development, etc.
M2 EQUITYBITES-March 9, 2015-Sucampo to return all licenses for intraocular pressure compound Unoprostone
Isopropyl to R-Tech Ueno
R-Tech Ueno will retain rights to unoprostone
isopropyl in Japan, Korea, Taiwan and the People's Republic of China for its approved indication, the treatment of Glaucoma and Ocular Hypertension.